Mirikizumab (Genetical Recombination)



Mirikizumab is a recombinant humanized monoclonal antibody composed of complementarity-determining regions derived from mouse anti-human interleukin-23α (p19) monoclonal antibody, human framework regions and human IgG4 constant regions. In the H-chain, the amino acid residues at positions 223, 229 and 230 are substituted by Pro, Ala and Ala, respectively, and C-terminal Lys is deleted. Mirikizumab is produced in Chinese hamster ovary cells. Mirikizumab is a glycoprotein (molecular weight: ca.147,000) composed of 2 H-chains (γ4-chains) consisting of 441 amino acid residues each and 2 L-chains (κ-chains) consisting of 214 amino acid residues each.

[1884201-71-1]